A study published in The Lancet reports that weekly semaglutide injections reduced heavy drinking in adults with obesity and ...

Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...

Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, ...

The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare.

BOSTON--(BUSINESS WIRE)--Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs that provide employers with transparent, ...

Eli Lilly & Co. surprised Wall Street by raising its annual sales and profit forecast, as demand for obesity medications ...

Americans' voracious appetite for GLP-1 weight loss drugs has the nation on pace to spend more than $1 trillion on ...

Some experts believe that anyone could benefit from GLP-1 medications, as the popular drugs have become more widespread and accessible. Others, however, warn that the decision to take the diabetes and ...

Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t ...

Incretin-based obesity medications may result in higher muscle-related loss vs. other weight loss strategies, according to data published in Annals of Internal Medicine.The findings “suggest that ...

Massachusetts and Rhode Island are considering dropping GLP-1 drugs for obesity treatment from their Medicaid programs, ...